Sennoside A (SA) is a natural dianthrone glycoside mainly from medicinal plants of Senna and Rhubarb. SA possesses numerous pharmacological properties, such as laxative, anti-obesity, hypoglycemic, hepatoprotective, anti-fibrotic, anti-inflammatory, anti-tumor, anti-bacterial, anti-fungal, anti-viral, and anti-neurodegenerative activities[3]. Sennoside A is a new scaffold for the development of HIV-1 dual RT (Reverse Transcriptase) inhibitors. Sennoside A also affected HIV-1 IN activity in vitro and HIV-1 replication in cell-based assays[4]. Plasma GLP-1 (Glucagon-like peptide-1) and insulin were markedly elevated by SA (Sennoside A) at the dosage of 45 mg/kg/day. Meanwhile, the increased phosphorylation status of EKR1/2 and prohormone convertase 1/3 (PC1/3) proteins were observed in the colon of SA-treated mice[5]. Sennoside A administration markedly improved the indices in T2D mice and obesity-related traits including blood glucose level, body weight, lipid metabolism disorder, and insulin resistance. Sennoside A also reduced inflammation and increased tight junction proteins in the ileum in gene-deficient mice via gut microbiota alteration[6].
搜索
